Skip to main content
. Author manuscript; available in PMC: 2023 Mar 24.
Published in final edited form as: Heart. 2023 Feb 23;109(6):470–477. doi: 10.1136/heartjnl-2022-321545

Table 2.

Incidence rate ratio and cox proportional analysis of cardiovascular outcomes and all-cause mortality between SGLT2i and non-SGLT2i cohorts

Outcomes Exposure Cases Incidence per 1000 patient-years Incidence rate ratio (95% CI) P-value Hazard ratio (95% CI) P-value SHR (95% CI) P-value
Heart failure hospitalization Non-SGLT2i 19 8.95 Reference 0.018 Reference 0.013 Reference 0.021
SGLT2i 5 2.92 0.33 (0.10–0.91) 0.28 (0.11–0.77) 0.32 (0.12–0.84)
All-cause mortality Non-SGLT2i 362 162.7 Reference <0.001 Reference <0.001 -
SGLT2i 124 70.0 0.43 (0.35–0.53) 0.35 (0.28–0.43)

Abbreviations: CI, confidence interval; SGLT2i, Sodium-glucose Cotransporter-2 Inhibitors; SHR, sub-distribution hazard ratio